Do analysts prefer TVGN or BCLI?

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 1,351.38%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Tevogen Bio is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, TVGN or BCLI?

Tevogen Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.63 N/A Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.65 N/A

Is TVGN or BCLI more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Brainstorm Cell Therapeutics N/A N/A -519.50%

Which has higher valuation and earnings, BCLI or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.65 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is BCLI or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Invizyne Technologies N/A N/A N/A

Do analysts recommend BCLI or ALGS?

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 457.16%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Does the media favor BCLI or ALGS?

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 0.93 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HOWL or BCLI?

Werewolf Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 324.04%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HOWL or BCLI more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Brainstorm Cell Therapeutics N/A N/A -519.50%

Does the media prefer HOWL or BCLI?

In the previous week, Werewolf Therapeutics had 4 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for Werewolf Therapeutics and 2 mentions for Brainstorm Cell Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.46 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCLI or CNTX?

Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 1,507.16%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has higher valuation and earnings, BCLI or CNTX?

Context Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.65 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is BCLI or CNTX more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Context Therapeutics N/A -82.06% -72.74%

Does the media favor BCLI or CNTX?

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 2 articles in the media. Context Therapeutics' average media sentiment score of 0.93 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainstorm Cell Therapeutics (BCLI) Competitors

$1.12 0.00 (0.00%)

As of 08/28/2026 03:55 PM Eastern

Compare

BCLI vs. TVGN, IZTC, ALGS, HOWL, and CNTX

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? Brainstorm Cell Therapeutics's main competitors and comparable companies include Tevogen Bio (TVGN), Invizyne Technologies (IZTC), Aligos Therapeutics (ALGS), Werewolf Therapeutics (HOWL), and Context Therapeutics (CNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 1 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.87 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Very Positive
Brainstorm Cell Therapeutics	Neutral

Tevogen Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Tevogen Bio has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 1,351.38%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Tevogen Bio is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Brainstorm Cell Therapeutics beats Tevogen Bio on 6 of the 11 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Invizyne Technologies?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Invizyne Technologies	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Brainstorm Cell Therapeutics had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 0 mentions for Invizyne Technologies. Brainstorm Cell Therapeutics' average media sentiment score of 0.34 beat Invizyne Technologies' score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Invizyne Technologies	Neutral

Summary

Brainstorm Cell Therapeutics beats Invizyne Technologies on 4 of the 5 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Aligos Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A
Aligos Therapeutics	$2.19M	19.69	-$24.19M	-$7.30	N/A

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 0.93 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 457.16%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Summary

Aligos Therapeutics beats Brainstorm Cell Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

In the previous week, Werewolf Therapeutics had 4 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for Werewolf Therapeutics and 2 mentions for Brainstorm Cell Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.46 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	24.39	-$60.82M	-$0.76	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Werewolf Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 324.04%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Werewolf Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

Werewolf Therapeutics beats Brainstorm Cell Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Context Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 1,507.16%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Context Therapeutics	N/A	-82.06%	-72.74%

Context Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 2 articles in the media. Context Therapeutics' average media sentiment score of 0.93 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainstorm Cell Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

Summary

Context Therapeutics beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCLI vs. The Competition

Export

Metric	Brainstorm Cell Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.78M	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.33	11.68	273.17	25.45
Price / Sales	N/A	1,404.95	637.71	104.31
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	-0.83	16.92	11.08	6.36
Net Income	-$11.62M	-$22.74M	$3.48B	$349.79M
7 Day Performance	12.33%	-0.13%	0.38%	-0.40%
1 Month Performance	24.81%	11.45%	7.89%	4.24%
1 Year Performance	48.00%	55.66%	24.71%	15.13%

Brainstorm Cell Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCLI Brainstorm Cell Therapeutics	N/A	$1.12 flat	N/A	+48.0%	$12.78M	N/A	N/A	40	Gap Up
TVGN Tevogen Bio	2.2604 of 5 stars	$6.97 +2.3%	$100.00 +1,334.7%	-84.9%	$44.34M	N/A	N/A	3	Positive News Gap Down
IZTC Invizyne Technologies	N/A	$6.95 -2.8%	N/A	-26.1%	$43.45M	N/A	N/A	29	Gap Down
ALGS Aligos Therapeutics	3.6638 of 5 stars	$7.47 +7.8%	$38.50 +415.4%	-34.5%	$43.28M	$2.19M	N/A	90
HOWL Werewolf Therapeutics	3.2521 of 5 stars	$0.89 +0.8%	$4.00 +349.4%	-28.0%	$42.93M	$1.88M	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. TVGN, IZTC, ALGS, HOWL, and CNTX

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Summary

How does Brainstorm Cell Therapeutics compare to Invizyne Technologies?

Summary

How does Brainstorm Cell Therapeutics compare to Aligos Therapeutics?

Summary

How does Brainstorm Cell Therapeutics compare to Werewolf Therapeutics?

Summary

How does Brainstorm Cell Therapeutics compare to Context Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. TVGN, IZTC, ALGS, HOWL, and CNTX

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Does the media prefer TVGN or BCLI?

Which has preferable earnings & valuation, TVGN or BCLI?

Is TVGN or BCLI more profitable?

Which has more risk and volatility, TVGN or BCLI?

Do insiders and institutionals believe in TVGN or BCLI?

Do analysts prefer TVGN or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Invizyne Technologies?

Do institutionals & insiders have more ownership in BCLI or IZTC?

Is BCLI or IZTC more profitable?

Which has higher valuation and earnings, BCLI or IZTC?

Does the media favor BCLI or IZTC?

Summary

How does Brainstorm Cell Therapeutics compare to Aligos Therapeutics?

Is BCLI or ALGS more profitable?

Do insiders & institutionals believe in BCLI or ALGS?

Which has better valuation and earnings, BCLI or ALGS?

Does the media favor BCLI or ALGS?

Do analysts recommend BCLI or ALGS?

Which has more risk and volatility, BCLI or ALGS?

Summary

How does Brainstorm Cell Therapeutics compare to Werewolf Therapeutics?

Does the media prefer HOWL or BCLI?

Is HOWL or BCLI more profitable?

Which has stronger earnings & valuation, HOWL or BCLI?

Do institutionals and insiders hold more shares of HOWL or BCLI?

Do analysts recommend HOWL or BCLI?

Which has more volatility and risk, HOWL or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Context Therapeutics?

Do analysts rate BCLI or CNTX?

Is BCLI or CNTX more profitable?

Which has higher valuation and earnings, BCLI or CNTX?

Do institutionals & insiders believe in BCLI or CNTX?

Does the media favor BCLI or CNTX?

Which has more volatility and risk, BCLI or CNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools